Moreover, gene and protein expression analysis has identified BCMA as the most selective target for relapsed/refractory multiple myeloma (refs. 17, 24, 25), making it a promising target for immunotherapy. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.